Table 4 Comparison of the number and percentage of cases meeting each criterion of Gerami and Gaiser, and CCND1 amplification between the acral and non-acral groups of melanoma
Acral group, n(%) | Non-acral group, n(%) | pa value | |
|---|---|---|---|
Total | 42 | 17 | |
Gerami’s criteria | |||
RREB1 > CEP6 (> 55%) | 6 (14.3) | 3 (17.6) | 1.000 |
RREB1 > 2 (> 29%) | 33 (78.6) | 11 (64.7) | .437 |
MYB<CEP6 (> 40%) | 19 (45.2) | 5 (29.4) | .262 |
CCND1 > 2 (> 38%) | 40 (95.2) | 14 (82.4) | .274 |
FISH positive | 41 (97.6) | 15 (88.2) | .197 |
Gaiser’s criteria | |||
RREB1 aberrant (> 63%) | 22 (52.4) | 6 (35.3) | .234 |
MYB<CEP6 (> 31%) | 21 (50.0) | 9 (52.9) | .838 |
MYB ≥ 2.5 | 21 (50.0) | 7 (41.2) | .539 |
CCND1 ≥ 2.5 | 39 (92.9) | 13 (76.5) | .187 |
FISH positive | 40 (95.2) | 15 (88.2) | .691 |
CCND1 copy numbers per cell,mean | 3.74 | 3.03 | .073 |
Percentage of cells with CCND1 > 2,mean | 76.74% | 58.67% | .007* |